CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Objective To determine the ability of CSF biomarkers to predict disease progression in progressive supranuclear palsy (PSP). Methods We compared the ability of baseline CSF β-amyloid1–42, tau, phosphorylated tau 181 (p-tau), and neurofilament light chain (NfL) concentrations, measured by INNO-BIA AlzBio3 or ELISA, to predict 52-week changes in clinical (PSP Rating Scale [PSPRS] and Schwab and England Activities of Daily Living [SEADL]), neuropsychological, and regional brain volumes on MRI using linear mixed effects models controlled for age, sex, and baseline disease severity, and Fisher F density curves to compare effect sizes in 50 patients with PSP. Similar analyses were done using plasma NfL measured by single molecule arrays in 141 patients. Results Higher CSF NfL concentration predicted more rapid decline (biomarker × time interaction) over 52 weeks in PSPRS (p = 0.004, false discovery rate–corrected) and SEADL (p = 0.008), whereas lower baseline CSF p-tau predicted faster decline on PSPRS (p = 0.004). Higher CSF tau concentrations predicted faster decline by SEADL (p = 0.004). The CSF NfL/p-tau ratio was superior for predicting change in PSPRS, compared to p-tau (p = 0.003) or NfL (p = 0.001) alone. Higher NfL concentrations in CSF or blood were associated with greater superior cerebellar peduncle atrophy (fixed effect, p ≤ 0.029 and 0.008, respectively). Conclusions Both CSF p-tau and NfL correlate with disease severity and rate of disease progression in PSP. The inverse correlation of p-tau with disease severity suggests a potentially different mechanism of tau pathology in PSP as compared to Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
Self-citationCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Self-citationKuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003680 · Cited by 506
Self-citationZetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487
Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485 · cited 1×
“It is uncertain how the results relate to other variant PSP phenotypes.(4) Finally, although the PSP-RS phenotype is highly specific for PSP pathology, the lack of neuropathologic data remains a relevant caveat.”
ResultSelf-citation
Research works printed but not linked: 15
- 10.1038/nrneurol.2016.5 · DOI
- 10.1002/mds.26987 · DOI · Paper page
- 10.1016/j.neurobiolaging.2016.02.034 · DOI · Paper page
- 10.1212/WNL.0000000000003154 · DOI · Paper page
- 10.1212/WNL.0000000000003688 · DOI · Paper page
- 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- 10.1093/brain/awm032 · DOI · Paper page
- Satz P, Uchiyama CL, White T. Color Trails Test. Professional Manual. Odessa: Psychological Assessment Resources; 1996.
- Kaplan RM, Saccuzzo DP. Psychological Testing: Principles, Applications and Issues. Belmont: Wadsworth; 2009.
- Heaton RK, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz: PAR; 2004.
- 10.1371/journal.pone.0022293 · DOI
- Alzheimer's Disease Neuroimaging Initiative (ADNI) Protocol [online]. Available at: adni.loni.usc.edu/wp-content/uploads/2010/09/ADNI_GeneralProceduresManual.pdf. Accessed April 1, 2017.
- 10.1016/j.parkreldis.2016.04.006 · DOI
- 10.1002/mds.26694 · DOI
- 10.1523/JNEUROSCI.3785-09.2010 · DOI · Paper page
Cited by
Neurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationNeurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Xia, Y., Prokop, S., & Giasson, B. I. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00460-5 · Cited by 218
Metadata
- Authors
- Rojas, J. C., Bang, J., Lobach, I. V., Tsai, R. M., Rabinovici, G. D., Miller, B. L., Boxer, A. L., AL-108-231 Investigators, Williams, D., Lafontaine, A. L., Marras, C., Jog, M., Panisset, M., Lang, A., Parker, L., Stewart, A. J., Corvol, J.-C., Azulay, J.-P., Couratier, P., Mollenhauer, B., Lorenzl, S., Ludolph, A., Benecke, R., Hoglinger, G., Lipp, A., Reichmann, H., Woitalla, D., Chan, D., Zermansky, A., Burn, D., Lees, A., Gozes, I., Boxer, A., Miller, B. L., Lobach, I. V., Roberson, E., Honig, L., Zamrini, E., Pahwa, R., Bordelon, Y., Driver-Dunkley, E., Lessig, S., Lew, M., Womack, K., Boeve, B., Ferrara, J., Hillis, A., Kaufer, D., Kumar, R., Xie, T., Gunzler, S., Zesiewicz, T., Dayalu, P., Golbe, L., Grossman, M., Jankovic, J., McGinnis, S., Santiago, A., Tuite, P., Isaacson, S., Leegwater-Kim, J., Litvan, I., Knopman, D. S., Schneider, L. S., Doody, R. S., Koestler, M., Jack, C. R., Van Deerlin, V., Randolph, C., Whitaker, S., Hirman, J., Gold, M., & Morimoto, B. H.
- Venue
- Neurology
- Published
- 2018-01-23
- Volume
- 90
- Issue
- 4
- Pages
- e273-e281
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2780749285
- Cited by
- 112
- References
- 20
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. https://app.cochat.ai/papers/10.1212/wnl.0000000000004859
- The paper
- Rojas, J. C., Bang, J., Lobach, I. V., Tsai, R. M., Rabinovici, G. D., Miller, B. L., Boxer, A. L., AL-108-231 Investigators, Williams, D., Lafontaine, A. L., Marras, C., Jog, M., Panisset, M., Lang, A., Parker, L., Stewart, A. J., Corvol, J.-C., Azulay, J.-P., Couratier, P., . . . Morimoto, B. H. (2018). CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. https://doi.org/10.1212/wnl.0000000000004859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.